Nerve Block Anesthesia Combined With Sedative Anesthesia Versus General Anesthesia in Surgery for CSDH
Safety of Nerve Block Anesthesia Combined With Sedative Anesthesia Versus General Anesthesia in Burr Hole Craniostomy With Drainage for Chronic Subdural Hematoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Liang Wu, M.D.
- Phone Number: +8601059975450
- Email: jasewl@sina.com
Study Contact Backup
- Name: Shu Li, M.D.
- Phone Number: +8601059976658
- Email: lishu@bjtth.org
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100050
- Recruiting
- Tiantan Hospital, Capital Medical University
-
Contact:
- Liang Wu, M.D.
- Phone Number: +8615001333582
- Email: jasewl@sina.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with chronic subdural hematoma with preoperative neurological dysfunction for burr hole drainage;
- Age beween 18 to 80
- Chronic subdural hematoma verified on cranial computed tomography or magnetic resonance imaging with hematoma thickness >1.0cm or midline shift >1.0 cm.
- Written informed consent obtained
Exclusion Criteria:
- Preoperative unconsciousness (Glasgow Coma Scale<13, or Markwalder Grade 2-4) or cognitive dysfunction (Mini-Cog≤3, or MMSE≤20)
- Preoperative sensory or motor aphasia
- Recurrence of hematoma with previous surgery for chronic subdural hematoma.
- Previous intracranial surgery or with intracranial lesion
- with severe comorbidity or other organ dysfunction
- Allergic to anesthetics
- Severe coagulopathy or high risk of life-threatening bleeding
- Participating in another research
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: General anesthesia (GA)
The GA group will receive general anesthesia.
|
Patients will be induced with propofol or etomidate, sufentanil , rocuronium or cisatracurium .
|
|
Experimental: Cranial nerve block anesthesia combined with sedative anesthesia (CNB-D)
The CNB-D group will receive cranial nerve block anesthesia combined with sedative anesthesia
|
Patients in the nerve block anesthesia combined with sedative anesthesia group will first receive cranial nerve blocks under standard monitoring.
At the same time, intravenous dexmedetomidine infusion is started for sedation at a rate of 2-4ug/kg for 10 minutes, followed by a continuous infusion of 0.5-1ug/kg/h until the Richmond Agitation-Sedation Scale (RASS) of -3.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of intraoperative body movement
Time Frame: During the surgery
|
Intraoperative body movement is defined as those likely to interfere with surgical procedures such as bending of hand and/or leg and movement of head.
|
During the surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recurrence rate at 6 months after surgery
Time Frame: From operation up to 6 months postoperatively
|
Rate of reoperations
|
From operation up to 6 months postoperatively
|
|
Neurological function
Time Frame: at discharge and 6 months after operation
|
Measured using Markwalder Grading Scale and the Modified Rankin Scale.
Markwalder Grading Scale ranges from grade 0 to 4, and the Modified Rankin Scale score ranges from 0 to 6.
|
at discharge and 6 months after operation
|
|
Conversion to general anesthesia
Time Frame: During the surgery
|
For the nerve block anesthesia combined with sedative anesthesia group, general anesthesia is performed if uncontrolled body movements still exist after opioid and sedative supplement.
|
During the surgery
|
|
Intraoperative awareness
Time Frame: 1 day after surgery
|
Measured with the Brice questionnaire.
Evaluate Intraoperative awareness through the following 6 questions:1.
What is the last thing you remember before going to sleep (please tick one box)?2.
What is the first thing you remember after waking up (please tick one box)?3.
Do you remember anything between going to sleep and waking up (please tick box)?4.
Did you dream during your procedure (please tick box)?5.
Were your dreams disturbing to you (please tick box)?6.
What was the worst thing about your operation (please tick box)?
|
1 day after surgery
|
|
Postoperative delirium
Time Frame: 1-5 days after surgery
|
POD will be assessed twice a day (before 09:00 and after 16:00) using the Richmond Agitation-Sedation Scale, the Confusion Assessment Method for Intensive Care Unit (CAM-ICU), and the 3- Minute Diagnostic Interview for CAM (3D-CAM).
|
1-5 days after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Weiming Liu, M.D., Beijing Tiantan Hospital
- Principal Investigator: Yuming Peng, M.D., Beijing Tiantan Hospital
Publications and helpful links
General Publications
- Wong HM, Woo XL, Goh CH, Chee PHC, Adenan AH, Tan PCS, Wong ASH. Chronic Subdural Hematoma Drainage Under Local Anesthesia with Sedation versus General Anesthesia and Its Outcome. World Neurosurg. 2022 Jan;157:e276-e285. doi: 10.1016/j.wneu.2021.10.074. Epub 2021 Oct 11.
- Ashry A, Al-Shami H, Gamal M, Salah AM. Local anesthesia versus general anesthesia for evacuation of chronic subdural hematoma in elderly patients above 70 years old. Surg Neurol Int. 2022 Jan 12;13:13. doi: 10.25259/SNI_425_2021. eCollection 2022.
- Liu HY, Yang LL, Dai XY, Li ZP. Local anesthesia with sedation and general anesthesia for the treatment of chronic subdural hematoma: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2022 Mar;26(5):1625-1631. doi: 10.26355/eurrev_202203_28230.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Disease Attributes
- Hemorrhage
- Craniocerebral Trauma
- Trauma, Nervous System
- Intracranial Hemorrhages
- Intracranial Hemorrhage, Traumatic
- Chronic Disease
- Hematoma
- Hematoma, Subdural
- Hematoma, Subdural, Chronic
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Anesthetics
- Hypnotics and Sedatives
Other Study ID Numbers
Other Study ID Numbers
- HX-B-2022078
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.